関連する実験動画

Updated: Jan 7, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.7K

エモディンとフィシオンは,加工されたポリゴナム・マルチフロームで特定された肝臓保護成分であるFXRを標的として,コレステート性肝臓損傷を軽減します. 2次元バイオクロマトグラフィーシステムを使用

Zhihui Li1, Yanqiu Gu1, Jianbo Yang2

  • 1Department of Pharmacy, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Frontiers in pharmacology
|January 5, 2026
PubMed
まとめ

No abstract available in PubMed .

キーワード:
FXR についてポリゴナム・マルチフロアム・タンブバイオクロマトグラフィ肝臓の損傷中国伝統医学

さらに関連する動画

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model08:20

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

Published on: December 2, 2022

2.2K

関連する概念動画

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
243